China Cell Biology Industry Conference & Biopharmaceutical Innovation Cooperation Conference (CBIC)CBIC

The China Cell Biology Industry Conference & Biopharmaceutical Innovation Cooperation Conference (CBIC) will cover key themes including antibody drugs, stem cells & regenerative medicine, immune cell therapy, cell-based drugs, 3D cell culture, cell multi-omics, organoids, exosomes, target screening, pharmaceutical innovation, novel vaccines, gene therapy, and oncolytic viruses. The conference will focus on hot topics such as the latest advancements in biotechnology, clinical applications, industrialization progress, investment and financing opportunities, industry standardization, and emerging regulatory trends.

The biopharmaceutical industry is one of China's key strategic emerging sectors. Currently, China ranks as the world's second-largest pharmaceutical market after the United States and is at a critical stage of strategic transition from "generic drugs" to "innovative drugs." Precision medicine is driving a revolution in drug R&D, while gene technology and cell engineering are bringing transformative changes to disease treatment. Medical devices are advancing toward intelligence and standardization, offering novel diagnostic and therapeutic approaches. Emerging biopharmaceutical service sectors, including Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), third-party testing, and health management, are continuously emerging and expanding, driving rapid growth in the biopharma industry. (Copyright of this content belongs to Juzhan. Reproduction without permission is strictly prohibited.)

In recent years, national and local governments have successively introduced a series of policies to promote the development of the bioeconomy. Three major biopharmaceutical hubs have emerged with distinct regional advantages: the Bohai Rim region (led by Beijing, Tianjin, Hebei, and Shandong), the Yangtze River Delta (centered on Shanghai, with Jiangsu and Zhejiang as its wings), and the Pearl River Delta (spearheaded by Guangzhou and Shenzhen). These key clusters have gained significant competitive advantages in industrial development.

The CBIC invites authoritative experts and industry leaders from academia, innovative pharmaceutical companies, research institutions, hospitals, biotech enterprises, health management and medical aesthetics sectors, venture capital and private equity firms, industrial parks, industry associations, and government regulatory bodies. Participants will gather to discuss the current state and future of the industry and share new development opportunities.

Concurrent with the CBIC, a thematic exhibition will be held to showcase the latest products, technologies, and services in the industry. By integrating national biopharmaceutical resources, the conference provides a one-stop platform for "academic exchange," "channel matchmaking," "market expansion," and "brand promotion," empowering the industry to achieve leapfrog development.